Mineralys Therapeutics director Karydas sells $85,740 in stock

Daphne Karydas, a director at Mineralys Therapeutics, sold 3,000 shares of the company's common stock for a total of $85,740, according to a filing with the U.S. Securities and Exchange Commission. The transaction took place on September 15, 2026, following the exercise of options to purchase the shares at a price of $12.02 per share.

The stock, currently trading at $27.98, has seen a 23% decline year-to-date. Ms. Karydas adopted a Rule 10b5-1 trading plan for these transactions on December 22, 2025. The stock option grant will vest in 36 monthly installments starting October 13, 2023. Ms. Karydas now holds 6,200 shares of Mineralys Therapeutics directly and retains ownership of 35,000 derivative securities in the form of stock options.

In a separate development, the company reported a larger-than-expected loss of $2.85 per share for the second quarter of 2026, exceeding analyst projections of $2.63 per share. This loss was largely due to increased spending ahead of the potential launch of its blood pressure drug, lorundrostat.